Maccura Bio expands investment, restructures for growth

Maccura Biotechnology [SZSE:300463] is strategically optimizing its operations with a series of key moves. The company will continue its cash management strategy for idle funds, capped at ¥60 million, to enhance efficiency. Investment in marketing networks will be expanded to include Beijing, Shanghai, and 11 other provinces, while the project's completion deadline is extended to December 31, 2026. to strengthen domestic marketing capabilities. In line with these strategic initiatives, Maccura Biotechnology is also streamlining its organizational structure to improve operational efficiency. These changes align with the company's long-term growth strategy and adaptation to evolving market conditions.